MA48051B1 - Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide - Google Patents

Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide

Info

Publication number
MA48051B1
MA48051B1 MA48051A MA48051A MA48051B1 MA 48051 B1 MA48051 B1 MA 48051B1 MA 48051 A MA48051 A MA 48051A MA 48051 A MA48051 A MA 48051A MA 48051 B1 MA48051 B1 MA 48051B1
Authority
MA
Morocco
Prior art keywords
indacen
hexahydro
sulfonamide
pyrazole
carbamoyl
Prior art date
Application number
MA48051A
Other languages
English (en)
Inventor
David Miller
Angus Macleod
Rio Gancedo Susana Del
Samuel Alexander Stratford
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of MA48051B1 publication Critical patent/MA48051B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un sel de sodium de n-((1,2,3,5,6,7-hexahydro-s-indacèn- 4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide et des hydrates, solvates et formes polymorphes de celui-ci. La présente invention concerne en outre des compositions pharmaceutiques comprenant ce composé, et l'utilisation de ce composé dans le traitement et la prévention de troubles médicaux et de maladies, plus particulièrement par inhibition de nlrp3.
MA48051A 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide MA48051B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1806578.9A GB201806578D0 (en) 2018-04-23 2018-04-23 Novel compound
PCT/EP2019/060311 WO2019206871A1 (fr) 2018-04-23 2019-04-23 Sel de sodium de n-((1,2,3,5,6,7-hexahydro-s-indacèn-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide

Publications (1)

Publication Number Publication Date
MA48051B1 true MA48051B1 (fr) 2020-08-31

Family

ID=62236309

Family Applications (2)

Application Number Title Priority Date Filing Date
MA48051A MA48051B1 (fr) 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
MA051082A MA51082A (fr) 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA051082A MA51082A (fr) 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide

Country Status (27)

Country Link
US (2) US10973803B2 (fr)
EP (2) EP3722281A1 (fr)
JP (1) JP7382958B2 (fr)
KR (1) KR20210005589A (fr)
CN (1) CN112020495B (fr)
AR (1) AR114827A1 (fr)
AU (1) AU2019257973A1 (fr)
BR (1) BR112020021650A2 (fr)
CA (1) CA3097832A1 (fr)
CY (1) CY1123260T1 (fr)
DK (1) DK3606909T3 (fr)
ES (1) ES2811228T3 (fr)
GB (1) GB201806578D0 (fr)
HR (1) HRP20201263T1 (fr)
HU (1) HUE050369T2 (fr)
LT (1) LT3606909T (fr)
MA (2) MA48051B1 (fr)
MD (1) MD3606909T2 (fr)
ME (1) ME03822B (fr)
MX (1) MX2020011196A (fr)
PL (1) PL3606909T3 (fr)
PT (1) PT3606909T (fr)
RS (1) RS60646B1 (fr)
SI (1) SI3606909T1 (fr)
TW (1) TW201943704A (fr)
UY (1) UY38186A (fr)
WO (1) WO2019206871A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201837021A (zh) 2017-01-23 2018-10-16 美商傑庫爾醫療股份有限公司 作為介白素-1活性抑制劑之化合物
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
AU2018317798A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP
EP3668840A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
KR20200041337A (ko) 2017-08-15 2020-04-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
WO2019034693A1 (fr) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
EP3707134A1 (fr) 2017-11-09 2020-09-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
WO2019166628A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
WO2019166619A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
EP3759090A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
WO2019166627A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
CA3104199A1 (fr) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Composes de sulfonyluree en tant qu'inhibiteurs de l'activite de l'interleukine 1
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
JP2023500925A (ja) * 2019-11-07 2023-01-11 インフレイゾーム リミテッド 神経炎症または炎症性脳疾患の処置および予防
WO2021089781A1 (fr) * 2019-11-07 2021-05-14 Inflazome Limited Traitement ou prévention de troubles cérébraux psychiatriques faisant appel à l'inhibiteur de nlrp3 n-((1,2,3,4-hexahydro-s-indacène-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment
CN114641287A (zh) * 2019-11-07 2022-06-17 英夫拉索姆有限公司 神经退行性病症的治疗和预防
EP4054564A1 (fr) * 2019-11-07 2022-09-14 Inflazome Limited Traitement de troubles auto-inflammatoires
WO2021089776A1 (fr) * 2019-11-07 2021-05-14 Inflazome Limited Traitement et prévention d'un trouble cérébral traumatique
WO2022023907A1 (fr) 2020-07-31 2022-02-03 Novartis Ag Méthodes de sélection et de traitement de patients présentant un risque élevé d'événements cardiaques indésirables majeurs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4802908A (en) * 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
EP1214087A1 (fr) * 1999-09-14 2002-06-19 Pfizer Products Inc. Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree
JPWO2013031931A1 (ja) * 2011-09-02 2015-03-23 協和発酵キリン株式会社 ケモカイン受容体活性調節剤
MD3259253T2 (ro) 2015-02-16 2020-06-30 Univ Queensland Sulfoniluree și compuși înrudiți și utilizări ale acestora
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
JP2019512009A (ja) 2016-02-16 2019-05-09 ザ・ユニバーシティ・オブ・クイーンズランド スルホニルウレアおよび関連化合物ならびにこれらの利用
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
WO2017184604A1 (fr) 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Composés et compositions destinés au traitement d'états associés à une activité de nlrp
EP3272739A1 (fr) 2016-07-20 2018-01-24 NodThera Limited Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes

Also Published As

Publication number Publication date
KR20210005589A (ko) 2021-01-14
CN112020495B (zh) 2024-05-17
DK3606909T3 (da) 2020-08-24
MD3606909T2 (ro) 2020-08-31
EP3606909A1 (fr) 2020-02-12
EP3722281A1 (fr) 2020-10-14
US20210315862A1 (en) 2021-10-14
TW201943704A (zh) 2019-11-16
AR114827A1 (es) 2020-10-21
PL3606909T3 (pl) 2020-11-16
AU2019257973A1 (en) 2020-11-19
UY38186A (es) 2019-11-29
JP2021522195A (ja) 2021-08-30
US10973803B2 (en) 2021-04-13
MA51082A (fr) 2021-05-19
CN112020495A (zh) 2020-12-01
BR112020021650A2 (pt) 2021-01-26
HRP20201263T1 (hr) 2021-02-05
LT3606909T (lt) 2020-10-12
GB201806578D0 (en) 2018-06-06
ME03822B (fr) 2021-04-20
EP3606909B1 (fr) 2020-05-27
ES2811228T3 (es) 2021-03-11
SI3606909T1 (sl) 2020-09-30
HUE050369T2 (hu) 2020-11-30
RS60646B1 (sr) 2020-09-30
US20200237723A1 (en) 2020-07-30
WO2019206871A1 (fr) 2019-10-31
JP7382958B2 (ja) 2023-11-17
CA3097832A1 (fr) 2019-10-31
MX2020011196A (es) 2020-11-13
PT3606909T (pt) 2020-07-09
CY1123260T1 (el) 2021-12-31

Similar Documents

Publication Publication Date Title
MA48051B1 (fr) Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MX2021004431A (es) Procesos novedosos.
WO2020106647A3 (fr) Polythérapie comprenant un inhibiteur de krasg12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA47970B1 (fr) Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
MA32903B1 (fr) Inhibiteurs de proteine-kinases
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
ATE368031T1 (de) Neue gamma secretase inhibitoren
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
MA27498A1 (fr) Compositions pharmaceutiques de sertaconazole pour utilisation vaginale.
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA34897B1 (fr) Formulations d'immunosupresseurs
EA202191286A1 (ru) Ингибитор 15-pgdh
HUP0102255A2 (hu) VLA-4 inhibitor hatású oMePUPA-V, ezt tartalmazó gyógyszerkészítmény és alkalmazása
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
MA53927B1 (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
DE60006542D1 (de) Verbindungen die die tryptase-activität hemmen